| HOME >> BIOLOGY >> TECHNOLOGY |
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Zoe Diane Draelos, M.D., clinical and research dermatologist and President of Dermatology Consulting Services, has joined the Company's Scientific Advisory Board.
San Diego (PRWEB) November 13, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Zoe Diane Draelos, M.D., clinical and research dermatologist and President of Dermatology Consulting Services, has joined the Company's Scientific Advisory Board.
Dr. Draelos is a board certified dermatologist in private practice, and a recognized expert in cosmetic and biologically active skin medication research. As President and Primary Investigator for Dermatology Consulting Services, a company she founded in 1988, Dr. Draelos is focused on providing education, developing formulation technology, and conducting clinical studies in association with the pharmaceutical and cosmetics industry.
Histogen recently announced the creation of Histogen Aesthetics LLC, a venture developing products for the growing medical aesthetic industries based on the Company's core technology. Dr. Draelos' addition to the Scientific Advisory Board will be invaluable as Histogen Aesthetics moves forward with product launches and further clinical evaluations in this area.
"To have Dr. Draelos, a renowned dermatologist, and skin biologist with focused expertise in cosmetic dermatology, join Histogen's SAB validates our technology and potential for treatments in the growing specialty of aesthetic medicine," stated Lawrence A. Rheins, Ph.D., President of Histogen Aesthetics LLC. "We are excited to have the opportunity to utilize her insight and clinical expertise as we prepare for product launches in post-resurfacing a
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |